Low Dose Naltrexone for Fatigue and Chronic Pain in Australia
| TL;DR |
| Low dose naltrexone (LDN) is an off-label medication being studied for chronic fatigue conditions including ME/CFS and long COVID, as well as a range of chronic pain syndromes. At doses of 1.5 to 4.5mg daily, LDN modulates neuroinflammation rather than blocking pain signals in the conventional sense. Early trial data and patient reports are encouraging. A 2024 Australian clinical trial is currently investigating LDN for ME/CFS and long COVID. For patients with persistent fatigue and chronic pain who have not responded to standard care, LDN is worth a conversation with an integrative GP. |
Fatigue that does not lift with rest. Pain that moves around the body without a clear pattern. Brain fog that makes simple tasks feel like climbing a hill. These are the symptoms that define conditions like Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), fibromyalgia, and long COVID.
They are also symptoms that many patients struggle to get taken seriously in a standard GP consultation, let alone treated effectively. The standard medications available for chronic pain, including antidepressants, anticonvulsants, and opioids, do not address the underlying biology that most current research points to: persistent neuroinflammation.
Low dose naltrexone (LDN) does. That is why it has attracted significant interest from researchers, integrative GPs, and patients over the past decade. This article explains how LDN works, what the evidence shows for fatigue and chronic pain specifically, and how to explore it as part of a broader care plan in Australia.
Why Fatigue and Chronic Pain Are So Hard to Treat
Conditions like ME/CFS, fibromyalgia, and chronic pain syndromes share a common thread that is increasingly well-documented in the research literature: central sensitisation and neuroinflammation.
Central sensitisation means the central nervous system has become hypersensitive. Pain signals are amplified. Normal sensations become uncomfortable. The threshold for what triggers a pain or fatigue response drops significantly. This is not a psychological phenomenon. It is a physiological one, measurable in immune markers and neuroimaging.
At the centre of this process are microglia: the immune cells of the brain and spinal cord. When chronically activated, microglia release a cascade of pro-inflammatory compounds, including cytokines, nitric oxide, and substance P.
Research from the Neuroinflammation, Pain and Fatigue Lab at the University of Alabama by Dr. Jarred Younger specifically links this chronic microglial activation to the symptom profile seen in fibromyalgia and ME/CFS.
The implication is significant: treating fatigue and chronic pain in these conditions may require addressing neuroinflammation, not just managing individual symptoms.
Can Low Dose Naltrexone Help with Chronic Fatigue?
| Direct Answer |
| Early evidence suggests LDN may reduce fatigue severity in ME/CFS, long COVID, and fibromyalgia by suppressing microglial overactivation and modulating immune function. A 2024 Australian clinical trial registered with the ANZCTR is specifically investigating LDN for ME/CFS and long COVID, with doses titrated from 1.5mg to a target of 4 to 6mg daily. A 2024 pilot study combining LDN with NAD+ in long COVID patients showed significant quality-of-life improvements and reduced fatigue scores over 12 weeks, with 52 percent of participants classified as responders. |
The pathway from LDN’s mechanism to fatigue relief is biologically coherent. Microglial activation causes “sickness behaviour”: the profound fatigue, malaise, and cognitive slowing that the body produces in response to infection or inflammation.
In conditions like ME/CFS and long COVID, this sickness behaviour appears to become self-sustaining rather than resolving when the trigger is gone.
LDN’s proposed action, suppressing microglial activation and modulating Toll-like receptor 4 (TLR4) signalling, addresses this directly. It is not a stimulant. It does not mask fatigue. It may reduce the inflammatory process that is generating it.
A separate mechanism has been identified in ME/CFS specifically. Research published in the PMC journal identified that ME/CFS patients show dysfunction in the TRPM3 ion channel in natural killer (NK) cells. LDN appears to restore TRPM3-like ionic currents in NK cells from ME/CFS patients, providing a measurable biological marker of its effect.
This is important: it suggests LDN may not just reduce subjective symptoms but address an identifiable physiological abnormality.
| Australian Clinical Trial Note |
| A double-blind randomised controlled trial of LDN for ME/CFS and long COVID is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR Trial ACTRN: 387311). Participants titrate from 1.5mg to a target of 4 to 6mg daily over 12 weeks. This is the kind of high-quality local evidence that will meaningfully advance LDN’s clinical standing in Australia. |
What Conditions Is LDN Being Used For in Chronic Pain Contexts?
Beyond fibromyalgia, LDN has been used or studied off-label in a range of chronic pain and fatigue conditions. An integrative GP is best placed to assess which of these is relevant to your situation.
| Condition | Evidence Status | What Is Being Reported |
|---|---|---|
| Fibromyalgia | Multiple RCTs and meta-analyses (2024 to 2025) | Reduced pain scores and improved Fibromyalgia Impact scores in some trials |
| ME/CFS | Small trials, RCT in progress (Australia) | Reduced fatigue, improved NK cell function, and better sleep in some patients |
| Long COVID fatigue | 2024 pilot study (LDN + NAD+) | 52% responder rate for quality of life and fatigue over 12 weeks |
| Crohn’s disease | Small blinded RCTs | Improved gastrointestinal symptoms |
| Multiple sclerosis | Small RCTs | Improved quality of life measures |
| Chronic widespread pain (nociplastic) | Off-label clinical use | Pain sensitivity reduction over time |
For conditions like fibromyalgia specifically, our companion article on fibromyalgia treatment with LDN covers the trial evidence in detail.
How LDN Fits into an Integrative Approach to Chronic Pain and Fatigue
| Direct Answer |
| LDN works best as part of a broader integrative care plan rather than as a standalone treatment. An integrative GP will consider it alongside pacing strategies for ME/CFS, dietary and nutritional support, sleep management, and other evidence-based interventions. LDN is not a replacement for physical rehabilitation, psychological support, or managing coexisting conditions. |
The language around LDN in patient communities can sometimes create unrealistic expectations. It is not a cure. Many patients see modest improvements over several months. Some do not respond.
A small number find that a different dose within the 1.5 to 4.5mg range works better for them than the standard titration.
An integrative GP at Holistica Health will approach your chronic fatigue or chronic pain as a clinical problem requiring a full assessment, not just a prescription.
That means reviewing your current medications and supplements, understanding the history and pattern of your symptoms, ordering relevant pathology if appropriate, and building a care plan that makes sense for your situation.
LDN may be one part of that plan. For some patients, it is a meaningful part.
How to Access LDN for Chronic Fatigue or Chronic Pain in Australia
LDN is available in Australia as a compounded preparation. Your GP prescribes it off-label and directs you to a compounding pharmacy. You do not need a specialist referral to start this conversation.
Steps to access LDN through Holistica Health:
- Complete the pre-screening eligibility check on the Holistica Health website. This takes two minutes and confirms that a telehealth consultation is appropriate.
- Book an integrative health consultation. The initial consultation is $99 and is available to patients across all Australian states and territories.
- Discuss your symptoms and history with your GP. If LDN is clinically appropriate, your GP will explain the dosing protocol, likely side effects, and what to monitor.
- If prescribed, your GP will direct you to a suitable Australian compounding pharmacy and schedule a follow-up to review your response.
| Compliance Note (AHPRA) |
| LDN is not TGA-approved for fatigue, ME/CFS, long COVID, or chronic pain. It is prescribed off-label. All prescribing decisions rest with the treating GP following individual clinical assessment. No guaranteed outcomes are claimed in this article. Clinical review by Dr. Wesam Abujalala and Dr. Keith is required before publication. Prescribing scope and clinical governance notes must be confirmed. |
The Bottom Line on LDN for Fatigue and Chronic Pain
Chronic fatigue and chronic pain are not conditions that respond easily to any single treatment.
But the emerging evidence for LDN points to a biologically coherent, relatively low-risk option for patients who are looking for something different from what standard medicine has offered them.
The Australian trial currently underway is exactly the kind of rigorous research needed to establish LDN’s place in clinical care.
In the meantime, off-label prescribing by informed, AHPRA-registered GPs continues to offer access to this therapy for patients who are appropriate candidates.
The first step is a conversation with a GP who is familiar with the evidence and with integrative approaches to chronic conditions.
| Book Your Integrative Health Consultation Today |
| Holistica Health offers integrative GP consultations for patients across Australia. No referral required. Initial consultation: $99. Available online from any Australian state or territory. Complete our pre-screening eligibility check to get started. |
Frequently Asked Questions
Is LDN the same as naltrexone used for addiction treatment?
Naltrexone is the same drug, but LDN is used at a much lower dose. Standard naltrexone for alcohol or opioid dependence is prescribed at 50mg daily. LDN for chronic pain and fatigue is prescribed at 1.5 to 4.5mg daily. At this low dose, it appears to act through a different mechanism, reducing neuroinflammation rather than primarily blocking opioid receptors.
Will LDN make me feel tired or sedated?
No. LDN is not sedating at therapeutic doses. In fact, patients who respond to it sometimes report improved energy alongside reduced pain. Vivid dreams or mild sleep disruption in the first few weeks is the most commonly reported initial effect, typically settling over 2 to 4 weeks.
Can LDN help with long COVID fatigue?
Early evidence suggests it may. A 2024 pilot study combining LDN with NAD+ in long COVID patients showed improved quality-of-life scores and reduced fatigue over 12 weeks, with 52 percent of participants classified as responders. An Australian clinical trial registered with the ANZCTR is currently investigating LDN specifically in ME/CFS and long COVID patients. These results are promising but not yet definitive.
How is LDN obtained in Australia?
LDN is prescribed off-label by an AHPRA-registered GP and dispensed by a compounding pharmacy. It is not available as a standard commercial product at the low doses used for chronic pain and fatigue. Compounding pharmacies in Australia are regulated by the TGA and are experienced with preparing LDN. Your GP will direct you to an appropriate pharmacy and specify the dose required.
What if LDN does not work for me?
Not everyone responds to LDN. If you do not see meaningful improvement after 3 to 6 months at the appropriate dose, your GP will review the situation and discuss alternative or complementary approaches. An integrative consultation covers more than any single medication: diet, sleep, pacing strategies, and other evidence-based interventions will also be part of the conversation.